91MO Randomized trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy to downstage ER+ve breast cancer: Breast Cancer Trials Group ANZ 1401 ELIMINATE trial

Murray, Nick; Francis, Prudence A.; Zdenkowski, Nicholas; Wilcken, Nicholas; Boyle, F.; Gebski, Val; Tiley, S.M.; Gilham, L.; Dawson, SJ; Loi, S.; Redfern, Andrew; Lombard, Janine; Spillane, AJ; Shadbolt, Clair; Badger, H.

doi:10.1016/j.annonc.2022.03.107

Cited by 3 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One article [15] employed patient Ki67 status for grouping, leading to a “High risk” rating. One article [21] referred to blindness, and was considered “Low risk.” Two articles [15,16] mentioned open label, and thus were rated “High risk.” In addition, articles that did not provide a detailed explanation were evaluated as “Unclear risk.” Five articles [13–15,22,23] mentioned withdrawing, and were rated “High risk.” None of the articles mentioned allocation concealment or other biases, resulting in an “Unclear risk” rating. All the articles demonstrated no selective reporting, they were considered “Low risk” (Fig.…”

Section: Resultsmentioning

confidence: 99%

“…6A). Among these articles, 6 studies, [13][14][15][16]19,21] specifically addressed Her2-patients, comprising a total of 864 enrolled individuals (465 in the NCET group and 399 in the NCT/NET group). Heterogeneity results were as follows: P = .31, I 2 = 16% (P > .1, I 2 < 50%), which led to the application of the fixed-effects model.…”

Section: Pathological Complete Responsementioning

confidence: 99%

“…We utilized the Cochrane Risk Assessment guidelines to evaluate the quality of the 11 articles included in the present study. [13][14][15][16][17][18][19][20][21][22][23] Four articles [14,18,21,22] provided clear descriptions of randomization methods, including computer-generated allowable blocks, minimization techniques and random number tables, warranting a "Low risk" rating. Six articles [13,16,17,19,20,23] mentioned random grouping but did not specify the allocation method, resulting in an "Unclear risk" rating.…”

Section: Risk Bias Assessmentmentioning

confidence: 99%

“…[13][14][15][16][17][18][19][20][21][22][23] Four articles [14,18,21,22] provided clear descriptions of randomization methods, including computer-generated allowable blocks, minimization techniques and random number tables, warranting a "Low risk" rating. Six articles [13,16,17,19,20,23] mentioned random grouping but did not specify the allocation method, resulting in an "Unclear risk" rating. One article [15] employed patient Ki67 status for grouping, leading to a "High risk" rating.…”

Section: Risk Bias Assessmentmentioning

confidence: 99%

See 3 more Smart Citations

Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis

Ma,

Shen,

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: This study aimed to conduct a comparative analysis of the efficacy and safety of neoadjuvant chemotherapy combined with endocrine therapy against the backdrop of single neoadjuvant chemotherapy or endocrine therapy, specifically in the context of hormone receptor-positive (HR+) breast cancer treatment. Methods: We conducted a thorough literature search across several databases, including China National Knowledge Infrastructure, Wanfang, Weipu, Chinese Journal Full-text Database, PubMed, Web of Science, Cochrane Library, and EMBASE, adhering to the guidelines outlined in the PRISMA statement. Our specific focus was on identifying randomized controlled trials that directly compared the combined approach of neoadjuvant chemotherapy and endocrine therapy with single chemotherapy or endocrine therapy in the context of treating HR+ breast cancer. Subsequently, we utilized statistical packages implemented in R software to perform comparative analyses of key clinical indicators, encompassing the complete response, objective response rate (ORR), disease control rate, pathological complete response (pCR), and adverse reactions. Results: A total of 11 randomized controlled trials, involving 1359 patients, all of whom met our inclusion criteria and were thus included in our comprehensive analysis. Within this cohort, 688 patients (50.63%) administered neoadjuvant chemotherapy combined with endocrine therapy (NCET), 642 patients (47.24%) received neoadjuvant chemotherapy (NCT) alone, while 29 patients (2.13%) underwent neoadjuvant endocrine therapy (NET) alone. The results of our meta-analysis revealed that NCET exhibited a statistically significant enhancement in both ORR and pCR (P < .05). Nonetheless, when compared to NCT or NET, NCET did not yield a significant impact on complete response, disease control rate, and safety (P > .05). In addition, NCET demonstrated a significant improvement in ORR among patients with HR+, HER2-negative breast cancer (P < .05). However, it was also linked to a heightened incidence of serious adverse reactions within this particular patient subgroup (P < .05). Conclusion: The combination of Neoadjuvant chemotherapy and endocrine therapy stands out as a significant contributor to enhancing the ORR and pCR for HR+ breast cancer patients. For breast cancer patients with HER2- status, NCET demonstrates a remarkable improvement in ORR but is also associated with the emergence of adverse reactions.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Pathological Complete Responsementioning

confidence: 99%

Section: Risk Bias Assessmentmentioning

confidence: 99%

Section: Risk Bias Assessmentmentioning

confidence: 99%

See 2 more Smart Citations

Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis

Ma,

Shen,

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…В нем сравнивалась эффективность комбинации ингибиторов ароматазы и химиотерапии по схеме AC-T против стандартной химиотерапии по схеме AC-T в неоадъювантном режиме. Результаты исследования показали, что нет статистически значимой разницы в снижении стадии до pT0/pT1 (23,5 % для группы химиогормонотерапии и 19,5 % для группы химиотерапии) [20].…”

Section: сравнение эффективности гормонотерапии в комбинации с химиот...unclassified

Preoperative Hormone Therapy in the Treatment of Breast Cancer: What Do We Know So Far?

Vorotnikov

Пахомова

Soinov

et al. 2022

Kreativnaâ hirurgiâ i onkologiâ

View full text Add to dashboard Cite

Breast cancer is the most common malignant disease in the world. One of the methods of treating breast cancer is neoadjuvant chemotherapy. Neoadjuvant chemotherapy (NCT) is now the standard of care for locally advanced breast cancer. Patients with HER2-positive and triple-negative breast cancer subtypes benefi t the most from NCT, with a 50–60 % chance of achieving pCR, while patients with hormone-sensitive, HER2-negative breast cancer subtypes have an average chance of achieving pCR of 10–20 %. For patients with locally advanced, hormone-sensitive Her2neu-negative breast cancer, neoadjuvant hormone therapy contributes to a tumor downstaging and an increasing rate of organ-preserving surgery. However, neoadjuvant hormone therapy is still not used routinely. There are a limited number of clinical guidelines that describe the choice of the optimal drugs, the optimal duration of hormone therapy and the criteria for selecting patients for preoperative hormone therapy. This is the first literature review in Russia that includes a systematization of the evidence regarding the effectiveness of neoadjuvant hormone therapy, a comparison of hormone therapy with neoadjuvant chemotherapy, comparison of hormonal drug groups, optimal duration of hormone therapy, attempts to combine hormone therapy with drugs of the group of selective CDK4/6 cyclin-dependent kinase inhibitors and phosphatidylinositol 3-kinase inhibitors for women with locally advanced hormone-sensitive Her2neu-negative breast cancer. The possibilities of using modern commercial multigene panels to assess the feasibility of identifying the cohort of patients for whom neoadjuvant hormone therapy would be most effective are also considered.

show abstract

Efficacy and safety of concomitant chemo-endocrine therapy in neoadjuvant treatment of hormone-positive HER2-negative breast cancer: a systematic review and meta-analysis

Ergün

Uçar

Akagündüz

2023

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

91MO Randomized trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy to downstage ER+ve breast cancer: Breast Cancer Trials Group ANZ 1401 ELIMINATE trial

Cited by 3 publications

References 0 publications

Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis

Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis

Preoperative Hormone Therapy in the Treatment of Breast Cancer: What Do We Know So Far?

Efficacy and safety of concomitant chemo-endocrine therapy in neoadjuvant treatment of hormone-positive HER2-negative breast cancer: a systematic review and meta-analysis

Contact Info

Product

Resources

About